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Atherosclerotic cardiovascular disease is the leading cause of death. Elevated circulating 
concentrations of lipids are a central pathogenetic driver of atherosclerosis. While numer-
ous effective therapies for this condition have been developed, there is substantial unmet 
need for this pandemic illness. Here, I will review nutritional, physiological, genetic, and 
pathological discoveries in the emerging zebrafish model for studying dyslipidemia and 
atherosclerosis. The technical and physiological advantages and the pharmacological 
potential of this organism for discovery and validation of dyslipidemia and atheroscle-
rosis targets are stressed through summary of recent findings. An emerging literature 
shows that zebrafish, through retention of a cetp ortholog gene and high sensitivity to 
ingestion of excess cholesterol, rapidly develops hypercholesterolemia, with a pattern of 
distribution of lipid species in lipoprotein particles similar to humans. Furthermore, recent 
studies leveraging the optical transparency of zebrafish larvae to monitor the fate of
these ingested lipids have provided exciting insights to the development of dyslipidemia 
and atherosclerosis. Future directions for investigation are considered, with particular
attention to the potential for in vivo cell biological study of atherosclerotic plaques.
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inTRODUCTiOn
Atherosclerosis is the leading cause of death (1). This chronic, progressive build-up of cholesterol, 
cellular debris, and calcium can narrow the lumens of critical arteries supplying the heart, brain, 
limbs, and organs. Plaques are mechanically weak structures and are prone to rupture. Once rup-
tured, a rapid thrombosis cascade is activated at the site of the plaque, occluding the artery and 
causing ischemic death to the supplied organ. Persons who have sustained an ischemic event in any 
artery are at substantially increased risk of repeated plaque rupture and thrombosis. While the last 
several decades have witnessed a decrease in the incidence of myocardial infarction and ischemic 
cerebrovascular accident, cardiovascular death is predicted to remain the leading killer for decades to 
come. A confluence of cardiovascular risk factors including tobacco exposure, hypertension, obesity 
in children and adults, type 2 diabetes mellitus, and non-alcoholic fatty liver disease is to blame 
for this trajectory (2–6). Moreover, there is widespread underutilization of effective antiplatelet, 
antihypertensive, and lipid lowering therapies (3, 7).
In the face of this clinical reality, I will argue in this minireview that zebrafish is an excellent 
system to discover and characterize new diagnostic and therapeutic targets for atherosclerosis. 
Those properties that make the study of lipid physiology and atherosclerosis in zebrafish potentially 
2Schlegel Zebrafish Dyslipidemia and Atherosclerosis
Frontiers in Endocrinology | www.frontiersin.org December 2016 | Volume 7 | Article 159
transformative will be reviewed, with an emphasis on original 
work as throughout the remainder of this article, stressing studies 
published since others and I last reviewed this topic (8, 9).
ZeBRAFiSH MODeL OveRview
The general strengths of zebrafish for biomedical research are 
well known, owing to its facile husbandry and low cost of hous-
ing and maintenance. This organism can be used to generate 
large numbers of externally fertilized embryos. These animals 
develop rapidly and are a mainstay of embryological, forward 
genetic, and pharmacological research (10–12). In the last 
decade, a full array of modern genome editing tools has been 
deployed in zebrafish, including very promising knock-in tech-
nologies (13–15). These advances have been married to progress 
in working in zebrafish late larvae, juveniles, and adults, where 
numerous aspects of physiology pertinent to atherosclerosis 
emerge.
GeneRAL FeATUReS OF LiPOPROTein 
MeTABOLiSM in ZeBRAFiSH
Lipoprotein Biology in Zebrafish
Elevated serum cholesterol and non-fasting triacylglycerol (TG) 
are central drivers of atherosclerosis (16–18). Understanding 
how lipids are absorbed from the diet, metabolized in tissues, 
and modified in atherosclerosis are central areas of investiga-
tion in developing newer and more effective therapies to treat 
atherosclerosis. A highly conserved system for transporting 
water-insoluble lipids is present in all animals (19). In particular, 
the apolipoprotein B (APOB)-coated particles produced by the 
intestine (chylomicrons) and liver [very low-density lipoprotein 
(VLDL) particles] are the carriers of the bulk of absorbed and 
resynthesized neutral lipids, cholesteryl esters (CE), and TG. 
These “β-lipoprotein” particles also carry fat-soluble vitamins A, 
D, and E from their sites of absorption or synthesis to their sites 
of use or storage (Figure 1).
In amniotes, two different protein products are encoded by a 
single APOB locus. In enterocytes of reptiles, birds, and mammals, 
the APOB pre-mRNA undergoes cytosine deamination (cata-
lyzed by APOBEC) to generate a transcript encoding a truncated 
protein (APOB48) that is found exclusively on chylomicrons 
(21). The full-length APOB transcript can be translated in both 
the liver and intestine (encoding APOB100). APOB48-coated 
chylomicron remnants are susceptible to rapid postprandial 
clearance by the liver, whereas APOB100-coated chylomicron 
remnants and VLDL remnants [intermediate density lipoprotein 
(IDL) particles] can mature into the long-lived and atherogenic 
low-density lipoprotein (LDL) particles (Figure  1). Thus, it is 
important to appreciate that Apob (operationally equivalent 
to “Apob100”)-coated zebrafish chylomicrons are, most likely, 
not cleared rapidly. Furthermore, zebrafish chylomicrons carry 
the potential to mature into LDL stoichiometrically (22). This 
lack of Apob48 might contribute to the rapid dyslipidemia and 
atherogenesis seen in dietary and genetic studies of zebrafish 
that will be discussed in subsequent sections. Finally, there are 
two zebrafish apob paralogs (two apob genes on different chro-
mosomes). The contribution (expression and incorporation into 
chylomicrons and VLDL) of these Apob paralogs to circulating 
β-lipoproteins and atherogenesis is not known; however, their 
larval expression patterns are different, and their encoded pro-
teins are structurally dissimilar, raising the possibility that they 
have unique functions (23).
Immediately beyond these critical issues of Apob biology, 
zebrafish utilizes highly conserved β-lipoprotein assembly pro-
teins and transport mechanisms. Gene expression survey and 
knockdown approaches confirmed that the central Apob-coated 
lipoprotein particle-producing enzyme microsomal triglyceride 
transfer protein (encoded by mtp and having orthologs in all 
species ranging from insects to mammals) is present and func-
tional in zebrafish yolk cell layer, liver, and intestine (24–26). 
More recently, studies on the intracellular trafficking of nascent 
chylomicrons have confirmed that the zebrafish model is well 
suited to investigating the molecular and cellular machinery of 
dietary energy harvest: the enterocyte undergoes stereotypical 
changes in ultrastructure when absorbing fats, and its secretory 
apparatus uses proteins conserved in evolution to pack and 
traffic nascent chylomicrons (27, 28). Finally, the major deter-
minant of clearance of LDL particles from the circulation, the 
LDL receptor (Ldlr), has conserved function in zebrafish (29). 
In short, zebrafish has a complement of conserved lipid traf-
ficking genes that renders study of lipid transport in this model 
organism relevant to human physiology. The next section will 
consider one additional, critical circulating protein that makes 
zebrafish lipoprotein biology particularly useful for modeling 
human lipoprotein biology.
Cholesteryl ester Transfer Protein (CeTP)
Following release into the circulation, lipoproteins are modified 
in zebrafish blood by enzymatic machinery that is also highly 
conserved with humans. Specifically, zebrafish carries an ortholog 
of the human CETP gene (30). CETP encodes a circulating 
protein that transfers CE from HDL particles to LDL particles in 
exchange for TG (Figure 2). Once loaded with TG and subject to 
additional modification, HDL is rendered more prone to rapid 
clearance, decreasing its “ability” to engage in atheroprotective 
processes such as reverse cholesterol transport (i.e., retrieving 
cholesterol from tissue macrophages to delivery to the liver and 
intestine for elimination). Likewise, increased CE loading of 
and depletion of TG from LDL contribute to atherogenesis by 
producing readily modifiable (oxidizable) small dense particles 
that can enter the subintimal space and drive atherogenesis 
(31–33). The net effect of Cetp function is to leave the organ-
ism with a higher concentration of atherogenic LDL particles 
and a lower concentration of atheroprotective HDL particles in 
circulation (the so-called “β-dominant” lipoprotein profile). In 
zebrafish, the fasting lipoprotein profile is β-dominant (34). This 
similarity to human lipoprotein composition reflects retention of 
a cetp ortholog in the zebrafish genome. As discussed below, this 
conservation of a critical human lipoprotein-modifying enzyme 
FiGURe 1 | intestinal and liver β-lipoprotein synthesis and vascular modification. Ingested lipids are hydrolyzed in the lumen of the intestine to absorbable 
species, such as free cholesterol, free fatty acids, and monoacylglycerol. These molecules are re-esterified in the enterocyte of the small intestine to triacylglycerol 
(TG), cholesteryl esters (CE), and phospholipids (not shown) and packaged into chylomicrons, whose signature coat protein in humans is Apob48 (one molecule per 
particle). This particle enters the vasculature and acquires an Apoc2 molecule from an HDL particle (not shown). Apoc2 is a required binding partner for lipoprotein 
lipase (LPL), an enzyme tethered to the apical surface of capillary bed endothelial cells in muscle and adipose tissues (20). LPL liberates free fatty acids for use by 
these tissues. The partially lipid-depleted chylomicron remnant is rapidly cleared by the liver through the action of Apoe-binding LRP receptors and Apob-binding 
low-density lipoprotein receptors (LDLR). The liver synthesizes very low-density lipoprotein (VLDL) particles from de novo lipogenesis-derived fatty acids and 
re-esterified fatty acids that reach the liver after adipocyte hydrolysis (and has relatively less CE in it). Human VLDL’s signature coat protein is Apob100. Following 
LPL-catalyzed lipid hydrolysis, VLDL remnants, intermediate density lipoprotein (IDL) particles, are either rapidly cleared by the liver or mature into LDL. LDL particles 
have a long circulating half-life, and they can deposit under vascular endothelial cells, undergo oxidation, and trigger an inflammatory atherosclerotic reaction with 
subsequent plaque rupture and thrombosis causing ischemia to the supplied tissue.
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renders zebrafish susceptible to a dyslipidemia with short dietary 
interventions. This conservation of a critical aspect of lipoprotein 
biology also opens the door to pharmacological intervention 
studies in zebrafish: many other, non-rodent laboratory models 
also fall short of recapitulating human lipoprotein composition 
and atherogenesis (35).
FiGURe 2 | Cholesteryl ester transfer protein (CeTP) in lipoprotein lipid exchange. Very low-density lipoprotein (VLDL) particles and HDL2 exchange 
triacylglycerol (TG) and cholesteryl esters (CE) in a reaction catalyzed by CETP. The depletion of TG and increase in VLDL CE (reflected in altered font sizes) coupled 
with lipoprotein lipase (LPL)- and hepatic lipase (HL)-mediated (further) depletion of TG (not shown) lead to the formation of small dense low-density lipoprotein 
(LDL), which is amenable to oxidative modification, a conversion central to driving subsequent atheromatous plaque formation. The transient increase in TG in HDL2 
(reflected in increased font size) delivers a substrate for HL-mediated hydrolysis (as it passes through the liver capillaries). This reaction generates small HDL3 and 
pre-β-HDL, which contain scant amounts of phospholipids only. Pre-β-HDL is removed from the circulation via renal filtration. The net effect of CETP action, thus, is 
to cause maturation of VLDL into atherogenic, small, dense LDL and to decrease atheroprotective HDL concentration. Apoa1 is the signature coat protein of HDL.
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A Cetp ortholog is absent in commonly used rodent models 
of dyslipidemia, rendering the study of atherosclerosis inherently 
difficult in these species. Specifically, rodents are resistant to ath-
erosclerosis because, among other things, they lack this enzyme’s 
action. Rodents have high circulating HDL concentrations and 
low LDL concentrations (the so-called “α-dominant” lipoprotein 
pattern) as a consequence of losing the Cetp gene (35). The most 
commonly used genetic strategy to trigger dyslipidemia in mice is 
to study dietary and genetic interventions in the context of delet-
ing the Apoe or Ldlr genes (36–40). Although they are widely used, 
these models do not capture the full biology of the corresponding 
human Mendelian diseases, familial dysbetalipoproteinemia (in 
the case of Apoe), and familial hypercholesterolemia (in the case 
of Ldlr): the HDL-cholesterol in both Apoe−/− or Ldlr−/− mice is still 
higher than in humans with APOE2/2 or LDLR−/− genotypes, and 
in both models, it is mainly the VLDL (and not the IDL and LDL, 
respectively) that increases. Furthermore, studies with only Apoe−/− 
or Ldlr−/− mouse models are often limited in generalizability: there 
is incomplete agreement in the findings with these two models 
(41). Beyond the limitations of standard mouse genetic models 
in driving atherogenic dyslipidemia, the atheromatous plaques 
that do form in mice lack features of “complex” human lesions. 
Indeed, to generate atheromatous plaques that appear more like 
human plaques, extreme physical stress is required in Apoe−/− 
animals deliberately maintained on a mixed genetic background 
(42). Even with this severe stress, plaque rupture (as in myocardial 
infarction) does not occur in rodents. Another supraphysiological 
approach to studying plaque rupture in mice that has met with 
some criticism because of its artificial nature involves causing a 
prolonged pharmacological hypertensive crisis in Apoe−/− animals; 
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this paradigm causes plaque rupture in the brachiocephalic artery, 
an uncommon site of rupture in humans (43).
ZeBRAFiSH DYSLiPiDeMiA MODeLS
High-Cholesterol Diet (HCD) Paradigm
The nutritional requirements of zebrafish are now known (44, 45). 
This knowledge has allowed several groups to establish conditions 
to induce metabolic stress by altering standard diets. For instance, 
zebrafish is susceptible to high-fat diet (HFD)-induced obesity, 
hyperglycemia, and dyslipidemia (46). The major breakthrough 
in applying zebrafish to the study of dyslipidemia was the devel-
opment of HCD (34, 47, 48). Not only do larvae and adults readily 
ingest such diets but also these animals demonstrate a series of 
responses that firmly established the utility of this organism in 
studying dyslipidemia and atherogenesis. First, HCD-challenge 
caused β-dominant hypercholesterolemia in adults; second, vas-
cular intimal lipid accumulation can be seen in larvae after short 
exposure to HCD, and these accumulated lipids attracted circulat-
ing monocytes; third, the extravasated LDL undergoes oxidation 
(to generate high-affinity ligands for innate immune receptors that 
are central for driving the inflammation of plaques); and fourth, 
the oxidized LDL particles can be tracked with live imaging (34, 
47, 48). This last observation was made via transgenic overexpres-
sion of the human monoclonal antibody IK17, which binds to 
malondialdehyde-modified LDL. The sustained overexpression 
of IK17 prevented HCD-induced sub-intimal lipid accumula-
tion (47). This is the first proof-of-principle demonstration that 
atherogenesis can be prevented in zebrafish through, presumably, 
accelerating immune complex-mediated clearance of modified 
LDL particles from the circulation (before they deposit in the 
walls of arteries). This constellation of findings sets the stage for 
future live imaging of atheromas in vivo, as discussed below.
CeTP Pharmacology
Natural compound extracts of cinnamon, clove, grape skin, 
laurel, loquat, and turmeric contain inhibitors of zebrafish 
Cetp (30, 49, 50). These extracts protect zebrafish from high-
cholesterol diet-induced dyslipidemia. Conversely, artificial 
sweeteners increase HDL particle-carried Cetp activity and drive 
hyperlipidemia (51, 52). Whether such zebrafish studies will 
translate into better inhibitors of human, CETP is difficult to 
predict; moreover, artificial sweeteners appear to exert multiple 
pathological effects, including triggering glucose intolerance by 
altering the gut microbiome (53). This pharmaceutical research 
space has been marked by several abandoned small molecules; 
one ongoing cardiovascular outcomes trial of a CETP inhibitor 
(http://ClinicalTrials.gov identifier NCT01252953) and a possi-
ble study of another inhibitor might provide opportunities for not 
only using this approach in humans but also to identify additional 
questions that might be answered with a zebrafish model (54, 55).
Zebrafish APOC2 Deficiency
A further advance in developing zebrafish dyslipidemia models 
comes from the targeted deletion of the apoc2 gene. Humans 
lacking APOC2 have familial chylomicronemia, a condition 
marked by high serum TG concentrations and propensity 
to recurrent bouts of pancreatitis (56). Zebrafish apoc2−/− 
mutants were generated with genome editing tools (22). 
These mutants demonstrated the hallmark finding of human 
APOC2 deficiency: decreased plasma lipase activity and severe 
hypertriglyceridemia (Figure  1). Their lipoprotein pattern is 
predominantly large, β-lipoproteins, as quantified with size-
exclusion chromatography and scanning electron microscopy 
techniques. Imaging of the vasculature in apoc2−/− mutants 
reveals accumulation of lipids and lipid-laden macrophages, 
both hallmarks of atherosclerotic plaques. This powerful dys-
lipidemia model might prove particularly useful in studying 
the steps of LDL extravasation, oxidation, and engulfment by 
vascular wall macrophages.
Zebrafish Liver X Receptor (LXR) Deletion
Lxrs are central inducers of cholesterol catabolism (57). These 
nuclear receptor transcription factors regulate metabolism 
through engaging oxysterol ligands and altering expression of 
functionally integrated genes involved in reverse cholesterol 
transport, lipoprotein modification, intestinal cholesterol 
absorption and excretion, liver fatty acid and TG regulation, bile 
transport, and immune and inflammatory signaling (57). There 
are two Lxr paralogs in mammals. Lxrα, which arose in fish, is 
mainly expressed in tissues involved in tissue macrophages, 
liver, and intestine, whereas Lxrβ, which arose in amphibians, is 
more widely expressed (58). Lxrα upregulates hepatic lipogenic 
enzymes and increases blood TG levels (59, 60). This seemingly 
self-defeating function—driving elimination of cholesterol while 
triggering fatty acid synthesis—has been a major impediment to 
developing Lxr-based therapeutics. Indeed, the LXRβ-selective 
agonist BMS-852927 not only promotes reverse cholesterol 
transport in humans but also induces hepatic de novo lipogenesis 
and attendant hypertriglyceridemia; BMS-852927 also causes a 
rapid decrease in circulating neutrophil counts in humans, but 
not in cynomolgus monkeys, underscoring the challenge of drug 
development (61).
Zebrafish bearing a targeted deletion mutation of the Lxrα gene 
nr1h3 develop severe hypercholesterolemia and hepatic steatosis 
when fed HCD and HFD (62). Conversely, overexpression of 
nr1h3 in enterocytes confers protection from dyslipidemia and 
hepatic steatosis when animals are fed a HFD; this metabolically 
beneficial effect of nr1h3 overexpression is due to the induction 
of a transcriptional program resulting in temporary enterocyte 
storage of lipids, delaying an en masse delivery of atherogenic 
lipoprotein particles in the circulation. As noted above, zebrafish 
chylomicrons likely mature into LDL particles because of their 
full-length Apob-coat protein. As such, the nr1h3 gene deletion 
and intestine-limited overexpression models might be useful for 
studying atherogenesis in that the increase in LDL-cholesterol 
seen in nr1h3−/− mutants is substantial. Furthermore, these 
studies may lead to the rational development of intestine-limited 
LXR agonists to blunt the development of dyslipidemia and 
atherosclerosis.
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THe FUTURe: ATHeROMA CeLL 
BiOLOGY, GeneTiC AnD 
PHARMACOLOGiCAL SCReenS, AnD 
CAnDiDATe Gene AnALYSeS
Cell Biology of Atherosclerosis In Vivo
There is no a  priori guarantee that zebrafish atheromas will 
model the full natural history of the human disease more 
closely in terms of mechanisms of development, inflammatory 
response, and final architecture than available models. However, 
if the advances in studying lipoprotein biology are any guides, 
the natural history of atheroma progression—from simple lipid 
accumulation below the vasculature to organization into “com-
plex,” cell-rich, and debris-rich plaques—should be feasible in 
zebrafish. In particular, live fluorescent markers of various cell 
types that accumulate within plaques such as vascular smooth 
muscles, macrophages, and other immune cells are available. 
These live imaging reporters could be used to monitor athero-
genesis in real time. Notably, such live imaging tools have been 
deployed with remarkable success in studying architecturally 
complex mycobacterial infection and host response in zebrafish 
(63–65). This success in modeling a human host response to 
mycobacteria in zebrafish—where other laboratory species have 
fallen short of producing human-like granulomas—is cause for 
hope that zebrafish atherosclerosis will reveal conserved inflam-
matory and immune mechanisms. In particular, the observation 
that zebrafish macrophages form granulomas in response to 
mycobacterial infection raises the hope that these cells may very 
well form lipid-laden “foam cells” in atherosclerotic plaques and, 
thus, drive an evolutionarily conserved inflammatory response 
that defines “complex” lesions (i.e., recruiting additional cells to 
the plaque and driving inflammation). Whether zebrafish will be 
useful in studying all aspects of more advanced atherosclerotic 
plaques biology is not clear. For instance, zebrafish have much 
lower blood pressure than terrestrial animals. Whether this 
organism will be useful for generating plaque rupture models 
is difficult to predict. Systematic histological examination of 
zebrafish arteries from dyslipidemia models will be required to 
determine what aspects of plaque biology can be studied in this 
model.
Genetic and Chemical Screens  
for Dyslipidemia and Atherosclerosis 
Modifiers
Beyond hemodynamic concerns regarding the natural history of 
zebrafish atherosclerosis, it remains uncertain whether genetic or 
pharmacological screens could be designed to look for modulators 
of dyslipidemia and atherogenesis in zebrafish. These complex 
phenotypes develop after a period of feeding in late larvae, raising 
the time and effort required to perform a large-scale screening 
project. Developing convenient reporters for the development of 
dyslipidemia and atherogenesis and their validation in already 
established zebrafish models would help guide screen design. 
Such an approach has proven feasible and informative in studying 
fasting glucose regulation in larvae (66, 67).
Candidate Genes
A large repertoire of genetic loci has been associated on a 
population genetics level with lipid parameters (68). For most, 
the molecular and cellular bases of the associations are unknown. 
While it is now experimentally tractable to rapidly overexpress 
and delete genes in zebrafish, phenotypic characterization for 
atherosclerosis is still limited in comparison to examination of 
alterations in glucose metabolism (for which larvae phenotypes 
develop more rapidly and do not require feeding). For instance, 
my group recently explored the mechanistic association of a 
single nucleotide polymorphism (SNP) in the FOXN3 locus with 
fasting blood glucose (69). Through a blend of primary human 
hepatocyte, immortalized HepG2 hepatoma cell, and transgenic 
zebrafish approaches, we found that this SNP increases the expres-
sion of the FOXN3 protein and that this transcriptional repressor 
blunts a glucose utilization transcriptional program in the liver. 
Overexpression of both human FOXN3 and zebrafish foxn3 in 
liver increased fasting blood glucose in adults. Whether this gene 
acts in other tissues to modulate blood glucose is not known. 
Neither is the mechanism through which the risk allele increases 
FOXN3 expression. An approach similar to the one used to study 
FOXN3 could be used to examine the effect of overexpressing 
candidate genes (in liver or elsewhere) on zebrafish lipoprotein 
metabolism, again, with the caveat that the experimental window 
will need to be larger. Those “hits” showing changes in circulating 
lipids could be explored further using a large collection of null 
alleles (70) or through genome editing approaches (including 
conditional alleles).
COnCLUSiOn
Through a combination of genetic, developmental, and physiologi-
cal advantages, the zebrafish has emerged as a major mechanistic 
discovery platform for studying dyslipidemia and atherosclerosis. 
Here, I highlighted individual areas of success using this organ-
ism, from dietary interventions, exploration of various aspects 
of lipoprotein production and processing, and genetic models 
for dyslipidemia and early atherosclerosis. Future work in the 
zebrafish system should include more thorough exploration of the 
composition and cellular architecture of atheromatous plaques, 
screenings effort to identify novel genes and small molecules 
that modulate atherogenesis, and candidate gene approaches to 
elucidating the functions of loci implicated in dyslipidemia and 
atherosclerosis through population genetic analyses. Collectively, 
this work in zebrafish may lead to the development of new and 
more effective therapies for dyslipidemia and atherosclerosis.
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